title: [Targeted chemotherapy of hepatocellular carcinoma using Lipiodol as a carrier].
abstract: For targeted chemotherapy using Lipiodol as a carrier, it was found that anticancer agents had to be dissolved in Lipiodol and diffused gradually from it. Dose forms having properties for targeted chemotherapy were named "oily anticancer agents". Oily anticancer agents are completely different from simple mixture of Lipiodol and anticancer agents by pumping methods in antitumor activities and adverse effects. Up to 1,601 arterial injections of oily anticancer agents were given to 400 patients with unresectable hepatocellular carcinoma. Decrease in serum AFP levels was observed in 209 (94%) of 222 AFP-positive patients, and reduction of tumor size was observed in 308 (96%) of 322 patients who had evaluable tumors. Reduction in size to less than 50% was observed in 50% of patients 5 to 6 months after initial administration, and all tumors reduced to less than 50% one year after. In 45 of 60 patients whose tumors shrank to less than 10% of initial size, follow-up 1 year or more after tumor shrinkage could be done (range 1-9 years, average 3 years). These tumors did not regrow, so they were considered to be cured. Survival was prolonged, especially in 251 patients who were good candidates for therapy (excluding those with Child C liver cirrhosis, tumor occupying all four segments of the liver, and/or extrahepatic spread at initial arterial injection of the drug), the 1-, 2-, and 5-year survival rates were 83, 58, and 34%, respectively.
authors.affiliation: First Dept. of Surgery, Kumamoto University School of Medicine.
authors.forename: T
authors.initials: T
authors.lastname: Konno
authors.forename: T
authors.initials: T
authors.lastname: Oda
authors.forename: A
authors.initials: A
authors.lastname: Nagamitsu
authors.forename: K
authors.initials: K
authors.lastname: Tabaru
authors.forename: R
authors.initials: R
authors.lastname: Yamashita
authors.forename: Y
authors.initials: Y
authors.lastname: Kai
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000473:pathology; D004337:Drug Carriers; D005260:Female; D006801:Humans; D007459:Iodized Oil / Q000008:administration & dosage*; D008103:Liver Cirrhosis / Q000188:drug therapy; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008299:Maleic Anhydrides / Q000008:administration & dosage; D008875:Middle Aged; D011137:Polystyrenes / Q000008:administration & dosage; D009353:Zinostatin / Q000008:administration & dosage / Q000031:analogs & derivatives
chemical_list: D000970:Antineoplastic Agents; D004337:Drug Carriers; D008299:Maleic Anhydrides; D011137:Polystyrenes; C035755:poly(maleic acid-styrene)neocarzinostatin; D007459:Iodized Oil; D009353:Zinostatin